Wnt activation as a therapeutic strategy in medulloblastoma
The Wnt molecular subgroup of medulloblastoma is associated with better prognosis than the other molecular subgroups. Here, the authors show that activating Wnt signaling impairs tumor development and improves survival in Group 3 and Group 4 medulloblastoma preclinical models.
Guardado en:
Autores principales: | Branavan Manoranjan, Chitra Venugopal, David Bakhshinyan, Ashley A. Adile, Laura Richards, Michelle M. Kameda-Smith, Owen Whitley, Anna Dvorkin-Gheva, Minomi Subapanditha, Neil Savage, Nazanin Tatari, Dillon McKenna, Blessing Bassey-Archibong, Neil Winegarden, Robin Hallett, John P. Provias, Blake Yarascavitch, Olufemi Ajani, Adam Fleming, Gary D. Bader, Trevor J. Pugh, Bradley W. Doble, Sheila K. Singh |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/90b86d3d0f9c41078f2e0a70337929d5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The transcriptional landscape of Shh medulloblastoma
por: Patryk Skowron, et al.
Publicado: (2021) -
Modeling medulloblastoma in vivo and with human cerebellar organoids
por: Claudio Ballabio, et al.
Publicado: (2020) -
CREB signaling activity correlates with differentiation and survival in medulloblastoma
por: Inna Armandari, et al.
Publicado: (2021) -
Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
por: Marta Buzzetti, et al.
Publicado: (2021) -
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Marije J. Voskamp, et al.
Publicado: (2021)